Glucagon receptor antagonists, preparation and therapeutic uses

A compound structurally represented by Formula I

• or a pharmaceutically acceptable salt thereof wherein:
• M is —CH2— or a bond;
• R1 and R2 are independently —H or -halogen;
• R3 is
• —(C1-C8)alkyl (optionally substituted with 1 to 3 halogens), —(C3-C7)cycloalkyl,
• —(C1-C6)alkyl-(C3-C7)cycloalkyl, or —(C3-C7)cycloalkyl-(C1-C6)alkyl (optionally substituted with 1 to 3 halogens);
• R4 and R5 are independently
• —H, -halogen, -hydroxy, hydroxymethyl, —CN, —(C1-C7)alkoxy,
• —(C2-C7)alkenyl, or —(C1-C6)alkyl (optionally substituted with 1 to 3 halogens);
• R6 is
• wherein the zig-zag mark shows the point of attachment to the parent molecule;
• R7 and R8 are independently
• —H, -halogen, —(C1-C6)alkyl (optionally substituted with 1 to 3 halogens),
• —(C1-C6)alkoxy, —(C3-C7)cycloalkyl, —C(O)R10, —COOR10, —OC(O)R10, —OS(O)2R10,
• —SR10, —S(O)R10, —S(O)2R10, or —O(C2-C7)alkenyl;
• R9 is independently
• —H, -halogen, —CN, —(C3-C7)cycloalkyl, —C(O)R10, —COOR10, —OC(O)R10,
• —OS(O)2R10, —SR10, —S(O)R10, —S(O)2R10, or —O(C2-C7)alkenyl, —(C1-C3)alkoxy (optionally substituted with 1 to 3 halogens), or —(C1-C6)alkyl (optionally substituted with 1 to 3 halogens);
• and
• R10 is independently at each occurrence
• -hydrogen, or —(C1-C6)alkyl (optionally substituted with 1 to 3 halogens).